A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307

HYPOTHESIS: Malignant mesotheliomas (MM) express VEGFR, PDGFR, and cKIT. Sorafenib is a potent inhibitor of the RAS/RAF/MEK pathway and also targets VEGFR and cKIT. We evaluated the activity of sorafenib in patients with unresectable mesothelioma. METHODS: MM patients who had received 0 to 1 prior c...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Dubey, Sarita, Jänne, Pasi A., Krug, Lee, Pang, Herbert, Wang, Xiaofei, Heinze, Robin, Watt, Colleen, Crawford, Jeff, Kratzke, Robert, Vokes, Everett, Kindler, Hedy Lee
Format: Artigo
Sprog:Inglês
Udgivet: 2010
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3823555/
https://ncbi.nlm.nih.gov/pubmed/20736856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181ec18db
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker